Nuveen’s Abeona Therapeutics ABEO Stock Holding History

Nuveen’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$511K	Buy	82,626 +25,907	+46%	+$142K	﹤0.01%	3261
2026 Q1	$254K	Hold	56,719	–	–	﹤0.01%	3038
2025 Q4	$299K	Hold	56,719	–	–	﹤0.01%	3045
2025 Q3	$299K	Hold	56,719	–	–	﹤0.01%	3061
2025 Q2	$322K	Buy	+56,719	New	+$323K	﹤0.01%	3021
2021 Q2	–	Sell	-44,757	Closed	-$2.1M	–	3350
2021 Q1	$2.1M	Buy	44,757 +32,113	+254%	+$1.77M	﹤0.01%	2588
2020 Q4	$496K	Buy	12,644 +112	+0.9%	+$3.81K	﹤0.01%	3046
2020 Q3	$320K	Buy	12,532 +2,961	+31%	+$187K	﹤0.01%	3071
2020 Q2	$697K	Sell	9,571 -9,714	-50%	-$671K	﹤0.01%	2778
2020 Q1	$1.01M	Buy	19,285 +12,611	+189%	+$842K	﹤0.01%	2509
2019 Q4	$546K	Sell	6,674 -193	-3%	-$13.6K	﹤0.01%	2886
2019 Q3	$388K	Sell	6,867 -1,994	-23%	-$149K	﹤0.01%	3011
2019 Q2	$1.06M	Buy	+8,861	New	+$1.49M	﹤0.01%	2709

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's ABEO Position: Q2 2026 in Review

Nuveen increased its Abeona Therapeutics (ABEO) stake by 46% in Q2 2026, buying an estimated $142K and bringing the position to 82,626 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #3261.

Nuveen first reported a position in ABEO in Q2 2019 and has held it in 13 quarters since. The position peaked at $2.1M in Q1 2021. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Nuveen held 82,626 shares of Abeona Therapeutics worth $511K as of Q2 2026.
Nuveen bought 25,907 Abeona Therapeutics shares in Q2 2026, an estimated $142K.
Abeona Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3261 holding.
Nuveen first reported a position in Abeona Therapeutics in Q2 2019 and has held it in 13 quarters since.
Nuveen's Abeona Therapeutics position peaked at $2.1M in Q1 2021.
127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.